Abstract
India contributes significantly to the global Plasmodium vivax burden. Treatment of malaria is more challenging than before owing to the rise of antimalarial drug resistance. The commonly used antimalarial drugs for treatment are chloroquine, antifolates like sulfadoxine-pyrimethamine, and artemisinin-based derivatives. Antimalarial resistance is studied by in vitro and in vivo methods. Study on mutations in the drug targets in the parasite is a widely used tool to help foresee likely resistance and relate to the clinical picture. The majority of studies on antimalarial resistance from the Southeast Asian region come from countries like Thailand and Myanmar. Though therapeutic failure with these antimalarial agents has not been reported in India, there have been reports of reduced clinical efficacy in the presence of mutations in their molecular targets.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of TROPICAL DISEASE & Health
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
